Press release

DSM reports Q3 2015 results

Heerlen, NL, 03 Nov 2015 07:15 CET

Highlights

  • Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange
  • Solid volume growth in Human Nutrition; very strong volume growth in Animal Nutrition
  • Nutrition EBITDA: negative impact of vitamin E and Swiss franc largely offset
  • Performance Materials EBITDA: improved on lower input costs and cost savings despite soft sales
  • Strong operating cash flow of €300 million
  • 2015 outlook maintained

Key figures & indicators

Q3 2015 Q3 2014 YoY in € million Volume Price/mix Exch. rate Other
      Group        
1,945 1,794 8% Sales 2% -1% 6% 1%
287 281 2% EBITDA        
      Nutrition        
1,253 1,091 15% Sales 6% 1% 6% 2%
213 225 -5% EBITDA        
      Performance Materials        
631 638 -1% Sales -3% -5% 7% 0%
102 87 17% EBITDA        

CEO statement

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “DSM continued to make good progress in Q3 in both EBITDA and cash generation. These results demonstrate the benefits of our focus on improving our operational performance. We are starting to implement the previously announced €125-150 million cost reduction program for the DSM-wide support functions. Tomorrow at our Capital Markets Day, we will announce our strategy and targets for the coming years, as well as an additional efficiency and cost reduction program in Nutrition.

It is increasingly difficult to predict macro-economic developments. Assuming no major changes in current market conditions for the remainder of this year, we maintain our full year outlook to deliver an EBITDA in 2015 ahead of 2014, the increase mainly driven by positive foreign exchange effects.”

Key figures & indicators

Q3 2015 Q3 2014 +/- in € million volume price/mix exch. rates other
      Net sales        
1,253 1,091 15% Nutrition 6% 1% 6% 2%
631 638 -1% Performance Materials -3% -5% 7%  
42 40 5% Innovation Center -5% -1% 11%  
19 25   Corporate Activities        
1,945 1,794 8% Total continuing operations 2% -1% 6% 1%
157 529   Discontinued  operations        
Q3 2015 Q3 2014 +/- in € million Jan - Sep 2015 Jan - Sep 2014 +/-
      EBITDA      
213 225 -5% Nutrition 616 650 -5%
102 87 17% Performance Materials 294 243 21%
0 -4   Innovation Center -8 -15  
-28 -27   Corporate Activities -88 -94  
287 281 2% Total continuing operations 814 784 4%
3 34   Discontinued operations 94 94  
123 132 -7% Core net profit (continuing operations) 340 360 -6%
106 113 -6% Net profit before exceptional items, continued operations 285 312 -9%
36 93 -61% Net profit after exceptional items, total DSM 65 252 -74%
123 132 -7% Core net profit (continuing operations) 340 360 -6%
106 113 -6% Net profit before exceptional items, continued operations 285 312 -9%
36 93 -61% Net profit after exceptional items, total DSM 65 252 -74%
0.7 0.76 -8% Core EPS (€/share) 1.95 2.08 -6%
0.59 0.64 -8% Net EPS before exceptional items, continuing operations (€/share) 1.61 1.78 -10%
0.19 0.51 -63% Net EPS after exceptional items, total DSM (€/share) 0.33 1.41 -77%
300 252   Cash flow from continuing operations 487 387  
113 87   Capital expenditures continuing operations (cash, net of customer funding) 321 269  
      Net debt 2,395 2,420*  

* Year-end 2014

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more